

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 July 2009 (02.07.2009)

PCT

(10) International Publication Number
WO 2009/080715 A3

(51) International Patent Classification:

A61K 39/015 (2006.01) A61K 47/18 (2006.01)
A61K 39/39 (2006.01)

(21) International Application Number:

PCT/EP2008/067925

(22) International Filing Date:

18 December 2008 (18.12.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/015,762 21 December 2007 (21.12.2007) US

(71) Applicant (for all designated States except US): **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LEMOINE, Dominique, Ingrid** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). **WAUTERS, Florence, Emilie, Jeanne, Francoise** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agents: **LOVATT, Victoria, Jayne** et al.; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,

KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

12 November 2009

(54) Title: VACCINES FOR MALARIA

(57) Abstract: The present invention relates to a component for a malaria vaccine comprising: a) an immunogenic particle RTS, S and/or b) an immunogenic particle derived from the CS protein of one or more *P. vivax* strains and S antigen from Hepatitis B and optionally unfused S antigen, or c) an immunogenic particle comprising RTS, CSV-S and optionally unfused S antigen, and d) a stabilizing agent comprising a stabilizing agent with at least one thiol functional group, or mixtures thereof. Methods for preparing the component, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the component and use of the latter, particularly in therapy are also disclosed.



WO 2009/080715 A3